VISA i hetero-VISA wsrod szczepow Staphylococcus aureus izolowanych z przypadkow klinicznych

• Autorzy: Mlynarczyk G. , Mlynarczyk A. , Luczak M.
• Języki publikacji: PL

Abstrakty

PL

Wśród szczepów Staphylococcus aureus izolowanych w latach 1993 - 2001 poszukiwano szczepów VISA i hetero-VISA. Wykazano obecność takich szczepów. Zastosowano różne modyfikacje oryginalnej metody i analizowano ich przydatność.

EN

The VISA (vancomycin intermediate Staphylococcus aureus) and hetero-VISA strains were found among all isolates of S. aureus obtained in the years 1997-2000. The frequency of VISA was 0,3% and h-VISA was about 3%. Most but not all of the h-VISA and all VISA strains were methicillin resistant. Moreover the usefulness of different methods enabling recognition of the h-VISA strains was compared.

Słowa kluczowe

PL

szczepy bakteryjne; mikrobiologia lekarska; szczepy hetero-VISA; szczepy VISA; Staphylococcus aureus

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2002
• Tom: 54
• Numer: 1
• Opis fizyczny: s.9-20,tab.,wykr.,bibliogr.

Twórcy

autor

Mlynarczyk G.

• Akademia Medyczna, Warszawa

autor

Mlynarczyk A.

autor

Luczak M.

Bibliografia

• 1. Aeschlimann JR, Hershberger E, Rybak MJ. Analysis of vancomycin population susceptibility profiles killing activity and postantibiotic effect against vancomycin-intermediate Staphylo#coccus aureus. Antimicrob Agents Chemother 1999; 43: 1914—18.
• 2. Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother 2000; 44: 3122-26.
• 3. Bierbaum G, Fuchs K, Lenz W i inni. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis 1999; 18: 691-96.
• 4. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000; 44: 272-77.
• 5. Chesneau O, Morvan A, Solh NE. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 2000; 45: 887-90.
• 6. Cui L, Murakami H, Kuwahara-Arai K i inni. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococ#cus aureus Mu50. Antimicrob Agents Chemother 2000; 44: 2276-85.
• 7. Hanaki H, Labischinski H, Inaba Y i inni. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-rcsistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 1998; 42: 315-20.
• 8. Hiramatsu K, Aritaka N, Hanaki H i inni. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350(9092): 1670-73.
• 9. Howe RA, Wootton M, Walsh TR i inni. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. J Antimicrob Chemother 1999; 44: 675-8.
• 10. Hubert SK, Mohammed JM, Fridkin SK i inni. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 1999; 37: 3590-93.
• 11. Jeljaszewicz J, Młynarczyk G, Młynarczyk A. Antibiotic resistance in Gram-positive cocci. Int J Antimicrob Agents 2000; 16: 473-78.
• 12. Kuroda M, Ohta T, Uchiyama I i inni. Whole genome sequencing of methicillin-resistant Staphylococcus aureus, the major hospital pathogen. Lancet 2001; 357: 1225-40.
• 13. Marchese A, Balistreri G, Tonoli E i inni. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866-69.
• 14. Młynarczyk G, Młynarczyk A, Łuczak M, Jeljaszewicz J. Charakterystyka klonu MRSA o obniżonej wrażliwości na wankomycynę Med Dośw Mikrobiol 2000; 52: 223-28.
• 15. Młynarczyk G, Młynarczyk A, Żabicka D, Jeljaszewicz J. Lysogenic conversion as a factor influencing the vancomycin tolerance phenomenon in Staphylococcus aureus. J Antimicrob Chemother 1997; 40: 136-7.
• 16. Murakami H, Matsumaru H, Kanamori M i inni. Cell wall-affecting antibiotic induce expression of a novel gene, drp35 in Staphylococcus aureus. Biochem Biophys Res Com 1999; 264: 348-51.
• 17. Peschel A, Vuong C, Otto M, Gotz F. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother 2000; 44: 2845-47.
• 18. Pfeltz RF, Singh VK, Schmidt JL i inni. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother 2000; 44: 294-303.
• 19. Sieradzki K, Pinho MG, Tomasz A. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chcm 1999; 274: 18942-6.
• 20. Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181: 7566-70.